Novel Agents and Treatment Strategies for Relapsed/Refractory MF
 | Novel Agents and Treatment Strategies for Relapsed/Refractory MF CME, CPE John Mascarenhas, MD | |
| Release Date: July 14, 2021 Expiration Date: July 14, 2022 | ||
Join Dr. Mascarenhas as he discusses new and emerging treatment approaches for relapsed/refractory myelofibrosis (MF). Topics include a review of the COMFORT-1 and -2 and the JAKARTA2 trials of ruxolitinib and fedratinib, and recently released outcomes of trials evaluating investigational agents such as momelotinib, pacritinib, navitoclax, pelabresib, and imetelstat. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation. | ||
| View Only, No Credit | ||